Back to top
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
ICU Medical, Inc. (ICUI) - $25 value - yours FREE >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ICU Medical, Inc. (ICUI) - $25 value - yours FREE >>
Image: Bigstock
Bruker Poised on Product Launches amid Near-Term Risks
On Jun 29, we issued an updated research report on Billerica, MA-based Bruker Corporation (BRKR - Free Report) − a global manufacturer of high-end analytical instruments used within the academic & government, pharma/biotech, clinical diagnostic and industrial markets. The company currently carries a Zacks Rank #2 (Buy).
During the last reported quarter (first-quarter 2016), Bruker expanded its existing MALDI Biotyper workflow’s menu to include selected high-value resistance testing for clinical microbiology research. The company also launched MBT Biotargets and introduced new research use-only capabilities to the MALDI Biotyper product portfolio.
In this regard, we currently look forward to the results of Bruker’s successful collaboration with the Special Bacteriology Reference Laboratory at the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, GA, for the creation of an expanded microorganism reference library for the MALDI Biotyper.
Further, other products that the company recently launched include a new, more comprehensive profiling module for detailed lipoprotein subclass analysis using Nuclear Magnetic Resonance (NMR).
Additionally, the honey profiling module of the NMR FoodScreener solution and the latest version of NMR wine screener module are noteworthy. Together, all products are expected to contribute significantly to Bruker’s revenues.
On the flip side, unfavorable currency translation continues to be a major dampener for the stock. Moreover, widespread macroeconomic uncertainties prevailing in countries like the U.S., Russia and certain European nations in which Bruker operates might hamper its revenue growth significantly, in case of any further economic downturn. Competitive headwinds also continue to pose threats to the stock.
Key Picks in the Sector
Some other well-ranked medical stocks are ICU Medical, Inc. (ICUI - Free Report) , LeMaitre Vascular, Inc. (LMAT - Free Report) and NuVasive, Inc. . All the three stocks carry a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>